What is Eagle Pharmaceuticals?
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of injectable products. Its primary focus areas include critical care and oncology, with a portfolio that features essential treatments such as argatroban for heparin-induced thrombocytopenia and Ryanodex for malignant hyperthermia. The company also offers non-alcohol docetaxel injection, a key chemotherapeutic agent, and Bendeka for specific hematological malignancies. Eagle Pharmaceuticals is actively advancing a pipeline of product candidates, including treatments for exertional heat stroke, drug-induced hyperthermia, lung cancer, mesothelioma, and breast cancer, demonstrating a commitment to addressing unmet medical needs through innovative pharmaceutical solutions.
How much funding has Eagle Pharmaceuticals raised?
Eagle Pharmaceuticals has raised a total of $200.3M across 2 funding rounds:
Stock Offering
$50.3M
Debt
$150M
Stock Issuance/Offering (2014): $50.3M, investors not publicly disclosed
Debt (2022): $150M led by J.P. Morgan Funds
Key Investors in Eagle Pharmaceuticals
J.P. Morgan Funds
J.P. Morgan Funds is a prominent global financial services entity, offering a comprehensive suite of solutions including investment banking, commercial banking, asset management, and wealth management. The firm supports a wide array of clients, from emerging startups to large corporations and institutional investors, across diverse industries, with a strategic emphasis on innovation and customized financial strategies.
What's next for Eagle Pharmaceuticals?
The recent major strategic investment signifies a pivotal moment for Eagle Pharmaceuticals, likely enabling the acceleration of its product development pipeline and the expansion of its commercial reach. This substantial capital infusion, coupled with the company's established expertise in complex injectable formulations, suggests a strategic focus on scaling operations, potentially through enhanced manufacturing capabilities, broader market penetration for existing products, and the advancement of its promising drug candidates through clinical trials and regulatory approvals. The company appears poised for significant growth and further entrenchment within the critical care and oncology pharmaceutical landscape.
See full Eagle Pharmaceuticals company page
